NQMC Update Service: May 4, 2015 ► National Committee for Quality Assurance

NQMC Update Service: May 4, 2015

National Committee for Quality Assurance

• Adherence to antipsychotic medications for individuals with schizophrenia: percentage of members 19 to 64 years of age during the measurement year with schizophrenia who were dispensed and remained on an antipsychotic medication for at least 80 percent of their treatment period. This updates a previously published measure summary.

• Antidepressant medication management (effective acute phase treatment): percentage of members 18 years of age and older who were treated with antidepressant medication, had a diagnosis of major depression and who remained on an antidepressant medication for at least 84 days (12 weeks). This updates a previously published measure summary.

• Antidepressant medication management (effective continuation phase treatment): percentage of members 18 years of age and older who were treated with antidepressant medication, had a diagnosis of major depression and who remained on an antidepressant medication for at least 180 days (6 months). This updates a previously published measure summary.

• Cardiovascular monitoring for people with cardiovascular disease and schizophrenia: percentage of members 18 to 64 years of age with schizophrenia and cardiovascular disease who had an LDL-C test during the measurement year. This updates a previously published measure summary.

• Diabetes monitoring for people with diabetes and schizophrenia: percentage of members 18 to 64 years of age with schizophrenia and diabetes who had both an LDL-C test and an HbA1c test during the measurement year.This updates a previously published measure summary.

• Diabetes screening for people with schizophrenia or bipolar disorder who are using antipsychotic medications: percentage of members 18 to 64 years of age with schizophrenia or bipolar disorder who were dispensed an antipsychotic medication and had a diabetes screening test during the measurement year. This updates a previously published measure summary.

• Follow-up after hospitalization for mental illness: percentage of discharges for members 6 years of age and older who were hospitalized for treatment of selected mental illness diagnoses and who had an outpatient visit, an intensive outpatient encounter, or partial hospitalization with a mental health practitioner within 30 days of discharge. This updates a previously published measure summary.

• Follow-up after hospitalization for mental illness: percentage of discharges for members 6 years of age and older who were hospitalized for treatment of selected mental illness diagnoses and who had an outpatient visit, an intensive outpatient encounter, or partial hospitalization with a mental health practitioner within 7 days of discharge. This updates a previously published measure summary.

• Follow-up care for children prescribed ADHD medication (continuation and maintenance [C&M] phase): percentage of members 6 to 12 years of age with an ambulatory prescription dispensed for ADHD medication who remained on the medication for at least 210 days and who, in addition to the visit in the initiation phase, had at least two follow-up visits with a practitioner within 270 days (9 months) after the initiation phase ended.This updates a previously published measure summary.

• Follow-up care for children prescribed ADHD medication (initiation phase): percentage of members 6 to 12 years of age with an ambulatory prescription dispensed for ADHD medication who had one follow-up visit with a practitioner with prescribing authority during the 30-day initiation phase. This updates a previously published measure summary.

• Metabolic monitoring for children and adolescents on antipsychotics: percentage of children and adolescents 1 to 17 years of age who had two or more antipsychotic prescriptions and had metabolic testing. This updates a previously published measure summary.

• Use of multiple concurrent antipsychotics in children and adolescents: percentage of children and adolescents 1 to 17 years of age who were on two or more concurrent antipsychotic medications. This updates a previously published measure summary.